Salerno S, Messana JM, Gremel GW, Dahlerus C, Hirth RA, Han P, et al. COVID-19 Risk Factors and Mortality Outcomes among Medicare Patients Receiving Long-term Dialysis. JAMA Netw Open. 2021;4(11):1–15.
Couchoud C, Bayer F, Ayav C, Béchade C, Brunet P, Chantrel F, et al. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. Kidney Int. 2020;98(6):1519–29.
Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98(6):1530–9.
Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020;98(1):20–6.
Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973–83.
Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–8.
Kho MML, Reinders MEJ, Baan CC, Baarle D Van, Bemelman FJ, Diavatopoulos DA, et al. The RECOVAC IR study : the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease , on dialysis or living with a kidney transplant. Nephrol Dial Transplant. 2021;36(9):1761–4.
Francis A, Baigent C, Ikizler TA, Cockwell P, Jha V. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. Vol. 99, Kidney International. Elsevier B.V.; 2021. 791–3.
Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. 2021;2204–6.
de Meester J, de Bacquer D, Naesens M, Meijers B, Couttenye MM, de Vriese AS. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: A regionwide registry study. J Am Soc Nephrol. 2021;32(2):385–96.
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature [Internet]. 2020;584(7821):430–6. Available from: https://doi.org/10.1038/s41586-020-2521-4.
Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Heal – Eur. 2021;8.
Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B Vaccine in Patients Receiving Hemodialysis. N Engl J Med. 1984;311(8):496–501.Available from: https://doi.org/10.1056/NEJM198408233110803.
Fuchshuber A, Kuhnemund O, Keuth B, Lutticken R, Michalk D, Querfeld U. Nephrology Dialysis Transplantation Pneumococcal vaccine in children and young adults with chronic renal disease. 1996;468–73.
Trial L term HAO label. Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on. YAJKD [Internet]. 2009;54(1):77–85. Available from: https://doi.org/10.1053/j.ajkd.2008.11.032.
Gallego-valcarce E, Shabaka A, Leon-poo M, Gruss E, Acedo-sanz JM, Cordón A, et al. Humoral Response Following Triple Dose of mRNA Vaccines Against SARS-CoV-2 in Hemodialysis Patients : Results After 1 Year of. 2022;9:1–12.
Peiyao R, Mengjie Y, Xiaogang S, Wenfang H. Immunogenicity and safety of SARS-CoV- vaccine in hemodialysis patients : A systematic review and.
Galmiche S, Binh L, Nguyen L, Tartour E, Lamballerie X De, Wittkop L, et al. Immunological and clinical ef fi cacy of COVID-19 vaccines in immunocompromised populations : a systematic review. Clin Microbiol Infect [Internet]. 2022;28(2):163–77. Available from: https://doi.org/10.1016/j.cmi.2021.09.036.
Angel-korman A, Peres E, Bryk G, Lustig Y, Indenbaum V, Amit S, et al. Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel : the case for a third vaccine dose. Clin Kidney J. 2022;15(2):226–34.
Espi M, Charmetant X, Barba T, Mathieu C, Pelletier C, Koppe L, et al. No Title. 2020.
Falahi S. Immunogenicity of COVID ‐ 19 mRNA vaccines in hemodialysis patients : Systematic review and meta ‐ analysis. 2022.
Wang H hao, Wu J ling, Chang M yu, Wu H mian, Ho L chun, Chi P jui, et al. Antibody Response and Adverse Events of AZD1222 COVID-19 Vaccination in Patients Undergoing Dialysis : A Prospective Cohort Study. 2022;
Garcia P, Anand S, Han J, Montez-Rath ME, Sun S, Shang T, et al. COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis. J Am Soc Nephrol. 2022;33(1):33–7.
Murt A. Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients : Is inactivated vaccine effective ? Ther Apher Dial. 2022;26(4):769–74.
Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, et al. SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. Ann Intern Med [Internet]. 2021;175(3):371–8. Available from: https://doi.org/10.7326/M21-4176.
Hsu CM, Weiner DE, Manley HJ, Aweh GN, Ladik V, Frament J, et al. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Clin J Am Soc Nephrol. 2022;17(3):403–13.
Strategic Advisory Group of Experts (SAGE), Parker E, Desai S, Wilder-Smith A, Hombach J, Marti M. Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. 2023.
Rodr D, Cuadrado E, Bedini L. Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients. 2022;
Melin J, Svensson MK, Albinsson B, Winqvist O, Pauksens K. A third dose SARS ‑ CoV ‑ 2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients. 2022;
Shashar M. Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients. Am J Nephrol. 2022;53(2–3):207–14.
Verdier JF, Boyer S, Chalmin F, Jeribi A, Egasse C, Maggi MF, et al. Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France. BMC Nephrol [Internet]. 2022;23(1):1–13. Available from: https://doi.org/10.1186/s12882-022-02751-5.
Wijewickrama ES, Herath N. Global Dialysis Perspective: Sri Lanka. Kidney360. 2022;3(9):1603–6.
Tan CW, Chia WN, Qin X, Liu P, Chen MIC, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol [Internet]. 2020;38(9):1073–8. Available from: https://doi.org/10.1038/s41587-020-0631-z.
Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet [Internet]. 2021;397(10282):1347–8. Available from: https://doi.org/10.1016/S0140-6736(21)00527-4.
Zhu F, Althaus T, Tan CW, Costantini A, Chia WN, Van Vinh CN, et al. WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. The Lancet Microbe. 2022;3(2):e81–2.
Lee SW. Regression analysis for continuous independent variables in medical research: statistical standard and guideline of Life Cycle Committee. Life Cycle. 2022;2:1–8.
Parker EPK, Horne EMF, Hulme WJ, Tazare J, Zheng B, Carr EJ, et al. Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study. Lancet Reg Heal – Eur [Internet]. 2023;30:100636. Available from: https://doi.org/10.1016/j.lanepe.2023.100636.
Kitamura M, Takazono T, Yamamoto K, Harada T, Funakoshi S, Mukae H, et al. Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case–control observational study. Ren Replace Ther [Internet]. 2022;8(1):1–9. Available from: https://doi.org/10.1186/s41100-022-00397-5.
Bai S, Dhrolia M, Qureshi H, Qureshi R, Nasir K, Ahmad A. Comparison of COVID-19 Inactivated Virus Vaccine Immunogenicity Between Healthy Individuals and Patients on Hemodialysis: A Single-Center Study From Pakistan. Cureus. 2022;14(4):e24153.
Füessl L, Lau T, Lean I, Hasmann S, Riedl B, Arend FM, et al. Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients. 2022;1–10.
Behrens GMN, Cossmann A, Stankov MV. Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting : The COVID-19 Contact ( CoCo ) Study in Healthcare Professionals. Infect Dis Ther. 2020;9(4):837–49.
Cheng CY, Hsiao SH, Fang TC, Lin YC, Wang JCC, Hung CS, et al. SARS-CoV2 antibody response after a third dose of heterologous ChAdOx1 nCoV-19 and Moderna vaccine in chronic dialysis patients. J Infect. 2022;84(6):e98–100.
Ranasinghe AV, Kumara GWGP, Karunarathna RH, De Silva AP, Sachintani KGD, Gunawardena JMCN, et al. The incidence, prevalence and trends of Chronic Kidney Disease and Chronic Kidney Disease of uncertain aetiology (CKDu) in the North Central Province of Sri Lanka: An analysis of 30,566 patients. BMC Nephrol. 2019;20(1):1–11.
Ben-Dov IZ, Oster Y, Tzukert K, Alster T, Bader R, Israeli R, et al. Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3–5 months follow-up. J Nephrol [Internet]. 2022;35(1):153–64. Available from: https://doi.org/10.1007/s40620-021-01210-y
Speer C, Goth D, Benning L, Buylaert M, Schaier M, Grenz J, et al. Early humoral responses of hemodialysis patients after covid-19 vaccination with bnt162b2. Clin J Am Soc Nephrol. 2021;16(7):1073–82.
Al-Muhaiteeb A, AlSahow A, Al-Yousef A, AlHelal B, Alrajab H, Bahbahani Y, et al. Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients—A prospective observational study. Hemodial Int. 2022;26(2):216–22.
Falahi S, Sayyadi H, Kenarkoohi A. Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis. Heal Sci Reports. 2022;5(6).
Affeldt P, Koehler FC, Brensing KA, Adam V, Burian J, Butt L, et al. Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients. 2022;1–14.
Cheng CY, Fang TC, Liao HW, Chen TH, Chang JH, Lin YC, et al. The Humoral Immune Response of the ChAdOx1 nCoV-19 Vaccine in Maintenance Dialysis Patients without Prior COVID-19 Infection. Vaccines. 2022;10(2).
Ling TC, Chen PL, Li NY, Ko WC, Sun CY, Chao JY, et al. Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis. Microbiol Spectr. 2023;11(2):1–13.
Prasithsirikul W, Nopsopon T, Phutrakool P, Suwanwattana P, Kantagowit P, Pongpirul W, et al. ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. Vaccines. 2022;10(6):959.
Glück V, Grobecker S, Köstler J, Tydykov L, Bertok M, Weidlich T, et al. Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel. Infection [Internet]. 2022;50(2):439–46. Available from: https://doi.org/10.1007/s15010-021-01703-9.
Gilboa M, Regev-Yochay G, Mandelboim M, Indenbaum V, Asraf K, Fluss R, et al. Durability of Immune Response after COVID-19 Booster Vaccination and Association with COVID-19 Omicron Infection. JAMA Netw Open. 2022;5(9):E2231778.
Sanders JSF, Messchendorp AL, De Vries RD, Baan CC, Van Baarle D, Van Binnendijk R, et al. Antibody and T-Cell Responses 6 Months after Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant. Clin Infect Dis [Internet]. 2023;76(3):E188–E199. Available from: https://doi.org/10.1093/cid/ciac557.
Bassi J, Giannini O, Silacci-Fregni C, Pertusini L, Hitz P, Terrot T, et al. Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS One. 2022;17(2):1–24.
Espi M, Charmetant X, Mathieu C, Lalande A, Decimo D, Koppe L, et al. Rapid Waning of Immune Memory Against SARS-CoV-2 in Maintenance Hemodialysis Patients After mRNA Vaccination and Impact of a Booster Dose. Kidney Int Reports [Internet]. 2023;8(4):907–11. Available from: https://doi.org/10.1016/j.ekir.2023.01.004.
Wang X, Han M, Fuentes LR, Thwin O, Grobe N, Wang K, et al. SARS-CoV-2 neutralizing antibody response after three doses of mRNA1273 vaccine and COVID-19 in hemodialysis patients. Front Nephrol. 2022;2:1–7.
Sanders JSF, Bemelman FJ, Messchendorp AL, Baan CC, Van Baarle D, Van Binnendijk R, et al. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation. 2022;106(4):821–34.
Chinnadurai R, Wu HHL, Cox E, Moore J, Clough T, Lamerton E, et al. Humoral Response in Hemodialysis Patients Following COVID-19 Vaccination and Breakthrough Infections during Delta and Omicron Variant Predominance. Vaccines. 2022;10(4):498.
Carr EJ, Wu M, Harvey R, Wall EC, Kelly G, Hussain S, et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Vol. 398, Lancet (London, England). 2021. 1038–41.
Agur T, Zingerman B, Ben-Dor N, Alkeesh W, Steinmetz T, Rachamimov R, et al. Humoral Response to the Third Dose of BNT162b2 COVID-19 Vaccine among Hemodialysis Patients. Nephron. 2022;
Tillmann F peter, Figiel L, Ricken J, Still H, Korte C, Plassmann G, et al. Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations , Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis : A Prospective Multi-Centre Cohort Study. 2021;
Robert T, Lano G, Giot M, Fourié T, Lamballeri X De, Jehel O, et al. Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis : loss of immunity , third dose and non-responders. Nephrol Dial Transplant. 2022;37(2):390–2.
Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. The Lancet Microbe [Internet]. 2022;3(1):e52–e61. Available from: https://doi.org/10.1016/S2666-5247(21)00267-6.
Nair MS, Ribeiro RM, Wang M, Bowen AD, Liu L, Guo Y, et al. Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost. iScience [Internet]. 2023;26(4):106345. Available from: https://doi.org/10.1016/j.isci.2023.106345.
Dopfer- A, Dulovic A, Affiliations A. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients. 2022;49(0):0–16.
Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2021;CJN.03500321.
Haarhaus M, Duhanes M, Leševic N, Matei B, Ramsauer B, Da Silva RR, et al. Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients. Scand J Immunol. 2022;95(5):1–6.
Van Praet J, Reynders M, De Bacquer D, Viaene L, Schoutteten MK, Caluwé R, et al. Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: A multicenter observational study. J Am Soc Nephrol. 2021;32(12):3208–20.
Galmiche S, Binh L, Nguyen L, Tartour E, Lamballerie X De, Wittkop L, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020.
Attias P, Sakhi H, Rieu P, Soorkia A, Assayag D, Bouhroum S, et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients. Vol. 99, Kidney international. 2021. 1490–2.
Haase M, Lesny P, Anderson M, Cloherty G, Stec M, Haase-Fielitz A, et al. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients: A multicenter prospective observational study. J Nephrol [Internet]. 2022;35(5):1467–78. Available from: https://doi.org/10.1007/s40620-022-01247-7.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03599-7